Core Viewpoint - The botulinum toxin industry in China is experiencing rapid growth, with the market size projected to increase from 1.9 billion yuan in 2017 to 9.9 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 26.6% [1][13]. Industry Overview - Botulinum toxin, originally used for treating muscle spasms, has become a popular choice in medical aesthetics due to its minimal invasiveness and quick recovery time [3][13]. - The application range of botulinum toxin is expanding beyond traditional uses like wrinkle reduction and facial slimming to include treatments for conditions such as migraines and muscle tension disorders [1][13]. Market Dynamics - The medical aesthetics market in China is projected to reach 288 billion yuan by 2024, with a year-on-year increase of 8.03%, indicating a growing consumer demand for beauty enhancement services [11][13]. - The market is characterized by a "six-way split" among leading products, with brands like Botox, Hengli, and Letyb gaining significant market shares [15][17]. Competitive Landscape - The botulinum toxin market is competitive, with established companies like Fosun Pharma, Haohai Biological Technology, and Lanzhou Biological Products Research Institute leading the industry [17][18]. - New entrants are emerging, leveraging innovative technologies and marketing strategies to capture market share [17]. Development Trends 1. **Increasing Industry Penetration** - As living standards rise, the penetration rate of medical aesthetics is expected to increase, particularly in lower-tier cities and rural areas, driven by a younger consumer base [23]. 2. **Enhanced Regulatory Oversight** - The government is intensifying regulations on botulinum toxin production and distribution to ensure safety and quality, which will promote the healthy development of the market [24]. 3. **Rise of Recombinant Botulinum Toxin** - Recombinant botulinum toxin is anticipated to become a future trend due to its lower biological risks, higher purity, and production efficiency, addressing limitations of traditional products [25].

Core Viewpoint - The controversy surrounding Juzhibio, a leading domestic cosmetics company, stems from allegations of ingredient fraud, particularly regarding its flagship product, "Kefumei" collagen stick, which has been accused of having significantly lower collagen content than claimed [1][2][3] Group 1: Impact on Company Valuation - Juzhibio's stock price has dropped approximately 30%, from a peak of 87 HKD per share to around 60 HKD, resulting in a market capitalization decline from over 900 billion HKD to about 650 billion HKD [3][22] - The allegations of ingredient fraud have severely impacted Juzhibio's market trust and financial standing, leading to a significant loss of over 250 billion HKD in market value within a short period [22] Group 2: Competitive Dynamics - The allegations against Juzhibio are not merely a case of a blogger exposing fraud but are linked to competitive tensions with Huaxi Biological, which has openly supported the allegations and has a financial stake in the blogger's company [2][5][6] - The conflict between Juzhibio and Huaxi Biological represents a broader battle for market dominance in the domestic skincare industry, reminiscent of past rivalries in the sector [5][6] Group 3: Ingredient Controversy - The core of the dispute lies in the ingredient claims, particularly the presence and concentration of recombinant human collagen, which is a key selling point for Juzhibio's products [12][16] - The rise of the "ingredient-focused" consumer trend has shifted market dynamics, with consumers increasingly prioritizing the efficacy and transparency of product ingredients [14][15] Group 4: Financial and Operational Insights - Juzhibio's operational model is characterized by low research and development (R&D) investment, with R&D expenses for 2024 amounting to only 1.07 billion CNY, representing just 1.9% of total revenue [18] - In contrast, Huaxi Biological invests significantly more in R&D, with a proportion of 8.68%, highlighting a structural difference in their approaches to innovation and product development [18] Group 5: Marketing Strategies - Juzhibio has heavily relied on marketing, with sales and distribution expenses reaching 20.08 billion CNY in 2024, accounting for 36.3% of total revenue, which is 19 times its R&D spending [18][19] - The company's strategy includes partnerships with top influencers, such as Li Jiaqi, to enhance brand visibility and consumer engagement [19][20] Group 6: Valuation Concerns - Juzhibio's current rolling price-to-earnings (P/E) ratio is approximately 29.5, which is significantly higher than the typical P/E ratio for consumer stocks, indicating potential overvaluation based on its growth narrative [21] - The ongoing "ingredient fraud" controversy poses a risk to Juzhibio's established trust and growth narrative, challenging its high valuation and market position [22]

Core Viewpoint - The first Global Aesthetic Technology Conference 2025 was held in Beijing, showcasing innovations in the medical aesthetics industry and promoting technology transfer and cross-industry collaboration [2]. Group 1: Awards Overview - The conference featured the announcement of the 2025 Global Aesthetic Technology Innovation Awards, which included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award [2]. Group 2: Technology Innovation Award Winners - Huaxi Biological was recognized for its integration of basic research and industrial transformation, particularly through its brand Runzhi, which focuses on high-quality materials for injection and tissue repair [5]. - Langxi Ziyuan Medical Devices developed a comprehensive technology system for regenerative medicine, enhancing exosome therapy for chronic wound repair with a 3D biomimetic culture system [6]. - Weimai Qingtong Medical Technology launched a new monopolar RF anti-aging system, YOUMAGIC, which has received both NMPA and FDA approvals, breaking international monopolies in high-end RF equipment [8]. - Suzhou Baifu Laser Technology specializes in high-end medical laser equipment, achieving significant technological breakthroughs in various laser types, enhancing treatment precision and safety [10]. - Suzhou Fumailai Medical Technology focuses on innovative design and application of high-end medical optical devices, achieving breakthroughs in energy stability and treatment accuracy [12]. - Guangzhou Yicheng Biological Technology emphasizes the development of innovative materials for injection fillers and sutures, providing reliable domestic raw material sources [13]. Group 3: Innovation Service Award Winners - Beijing Tonghe Litai Bio-Tech specializes in preclinical research for medical devices, having completed over 900 NMPA registration reports, ensuring scientific data and compliance for innovative products [16]. - Beijing Baoli Yongchang Medical Technology (Lihe Kang) has developed a mature methodology for compliance transformation services in the medical aesthetics field, facilitating the rapid market entry of innovative products [17]. - Hainan Susong Biological Technology introduced Swiss SmartBone® on Demand bone regeneration materials, demonstrating effective cross-border medical technology integration [19]. Group 4: Innovation Transformation Award Winners - Yao Guijin led the establishment of an ecosystem for medical aesthetic technology transformation, connecting medical, research, enterprise, and regulatory sectors [21]. - Professor An Yang's team developed solutions for nasal reconstruction, enhancing tissue regeneration and application in aesthetic surgery [22]. - Professor Niu Xufeng innovated a composite material system for skin fillers, addressing common industry challenges and improving product stability [23]. - Professor Zhang Guifeng achieved breakthroughs in medical collagen research, establishing a closed-loop system for industry standards and quality control [24]. Conclusion - The awards highlighted the breadth and depth of innovation in the medical aesthetics sector, showcasing the emerging strength of Chinese companies and experts in the global industry landscape [25].

Core Viewpoint - The first Global Aesthetic Technology Conference 2025 was held in Beijing, showcasing innovations in the medical aesthetics industry and promoting technology transfer and cross-industry collaboration [2] Group 1: Awards Overview - The conference featured the 2025 Global Aesthetic Technology Innovation Awards, which included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award, highlighting innovations in materials, equipment, and technology transfer in China's medical aesthetics sector [2] Group 2: Technology Innovation Award Winners - Huaxi Biological was recognized for its integration of basic research and industrial transformation, particularly through its brand Runzhi, which utilizes synthetic biology technology in hyaluronic acid and extracellular matrix [4] - Langxi Ziyuan Medical Devices focused on regenerative medicine and developed a 3D biomimetic culture system that enhances the yield and bioactivity of exosomes for chronic wound repair [5] - Weimai Qingtong Medical Technology created a new monopolar RF anti-aging system, YOUMAGIC, which has received both NMPA and FDA approvals, breaking the international brand monopoly in high-end RF equipment [7] - Suzhou Baifu Laser Technology specializes in high-end medical laser equipment, achieving significant technological breakthroughs in stability and precision, with products that meet international standards [9] - Suzhou Fumai Lei Medical Technology has developed innovative high-end medical optical devices, focusing on energy stability and treatment precision, contributing to the rise of domestic optical medical equipment [11] - Guangzhou Yicheng Biological focuses on regenerative materials and has developed various medical devices with a clear product line and compliance registration paths [12] Group 3: Innovation Service Award Winners - Beijing Tonghe Litai Biotechnology specializes in preclinical research for medical devices, having completed over 900 NMPA registration reports, ensuring scientific data and compliance for innovative medical products [14] - Beijing Baoli Yongchang Medical Technology (Lihokang) has established a mature methodology for compliance transformation services in the medical aesthetics field, facilitating the rapid market entry of innovative products [16] - Hainan Susong Biotechnology has introduced Swiss SmartBone® on Demand bone regeneration materials, demonstrating effective cross-border medical technology integration and personalized medical needs [17] Group 4: Innovation Transformation Award Winners - Yao Guijin led the establishment of an ecosystem for medical aesthetics technology transfer, facilitating collaboration among medical, research, enterprise, and regulatory sectors [19] - Professor An Yang's team developed solutions for nasal reconstruction, achieving significant advancements in tissue regeneration and repair [20] - Professor Niu Xufeng addressed common issues in skin fillers by innovating a polyester microsphere/collagen composite material system, enhancing stability and integration [21] - Professor Zhang Guifeng made breakthroughs in medical collagen research, establishing a closed-loop system for industry standards and quality control [22] Conclusion - The Global Aesthetic Technology Awards highlighted the breadth and depth of innovation in the medical aesthetics sector, showcasing the emerging strength of Chinese companies and experts in the global industry landscape [23]

Key Insights - The report highlights the significant performance of high-volatility strategies, with a cumulative increase of over 27% year-to-date, indicating strong market recovery and strategy effectiveness [2][4] - The report emphasizes the strategic transformation of Huaxi Biological, a leading global hyaluronic acid supplier, which is expected to benefit from domestic consumption upgrades and the growing demand for life health products [7][10] - The mechanical industry shows a mixed performance, with a decline in domestic excavator sales but a positive export growth, suggesting a resilient long-term outlook supported by government initiatives [12][15][16] - The beverage sector, particularly beer companies, is exploring diversification into non-alcoholic beverages, which is seen as a crucial growth strategy for future revenue streams [18][22] Group 1: High-Volatility Strategies - The report details the performance of various strategies, with low-price enhancement, improved dual-low, and high-price high-elasticity strategies yielding returns of 1.5%, 2.7%, and 4.7% respectively during the last period [2][3] - Year-to-date performance for these strategies shows returns of 4.5%, 16.6%, and 27.3%, outperforming the benchmark [2][3] Group 2: Huaxi Biological - Huaxi Biological is positioned as a global leader in bioactive materials, focusing on synthetic biology technology and a comprehensive industry chain [7][10] - The company is expanding its product matrix to include various bioactive materials, enhancing its market presence in medical and nutritional products [8][9] Group 3: Mechanical Industry - In May, domestic excavator sales decreased by 1.48%, while exports grew by 5.4%, indicating a shift in market dynamics [12][14] - The report notes that the overall export of engineering machinery remains stable, with significant growth in exports to Africa and South America [14][16] Group 4: Beverage Sector - Domestic beer companies are actively expanding into beverage markets, with notable initiatives from brands like Yanjing and Qingdao Beer [18][19] - The report suggests that while beverage business contributions are currently low, they represent a vital growth avenue for beer companies in the long term [22]

Economic Overview - Quanzhou has a population of 8.914 million and a GDP of 1.31 trillion yuan for 2024, with a year-on-year growth of 6.5% [1] - Jinan has a population of 9.515 million and a GDP of 1.35 trillion yuan for 2024, with a year-on-year growth of 5.4% [1] - Jinan excels in economic total and service industry capabilities, benefiting from provincial resource aggregation [1] Healthcare Resources - Quanzhou has 7 tertiary hospitals with a bed density of 6.8 per thousand people [4] - Jinan has 25 tertiary hospitals with a bed density of 9.3 per thousand people, leading in high-end medical resource concentration [4] Higher Education and Innovation - Quanzhou has 12 universities with a research funding intensity of 2.3%, focusing on digitalization in textiles and semiconductors [6] - Jinan has 52 universities with a research funding intensity of 2.8%, supporting innovation in aerospace information and biomedicine [6] Industrial Competitiveness - Quanzhou's key industries include textiles and new sectors like semiconductors, with a 7.8% increase in industrial added value for 2024 [9] - Jinan is recognized for advanced manufacturing, with significant production in heavy trucks and a 150% increase in new energy vehicle output [9] Transportation Hub Status - Quanzhou relies on the Fuxia high-speed railway and has a port with a cargo throughput of 120 million tons for 2024 [11] - Jinan has a port with a throughput exceeding 10 million tons and a high-speed rail network of 520 kilometers, enhancing its strategic value [11] Tourism and City Branding - Quanzhou attracts over 100 million tourists in 2024, leveraging its maritime trade heritage [13] - Jinan generates over 120 billion yuan in tourism revenue, benefiting from its natural springs and cultural attractions [13] Livelihood and Urban Balance - Quanzhou's per capita disposable income is 52,000 yuan, with a rural-urban income ratio of 2.3:1 [15] - Jinan's per capita disposable income is 54,000 yuan, with a more balanced rural-urban income ratio of 2.0:1 [15] Urban Strength - Quanzhou has an urban area of 230 square kilometers and an urbanization rate of 71.19% [17] - Jinan has a larger urban area of 865.6 square kilometers and a higher urbanization rate of 76.2% [17] Industrial Transformation Potential - Quanzhou focuses on intelligent upgrades in textiles and new energy sectors, with a digital economy growth of 18.3% [19] - Jinan emphasizes aerospace information and biomedicine, with a high-tech manufacturing value increase of 14.4% [19] Summary of Strengths - Quanzhou excels in private economic vitality and maritime economic resilience, leveraging its manufacturing clusters and global trade networks [21] - Jinan leads in economic total, per capita GDP, innovation, transportation, tourism, and public services, showcasing its provincial capital advantages [23] Conclusion - Quanzhou is recognized for its dynamic private sector and maritime industry, while Jinan is noted for its comprehensive urban strength and innovation capabilities [25][27]

中国北京建国门外大街 1 号国贸写字楼 2 座 12 -15 层 100004 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、 《上市公司股东会规则》(以下简称"《股 东会规则》")等法律、法规及规范性文件和《华熙生物科技股份有限公司章程》 (以下简称"《公司章程》")的规定，北京市通商律师事务所(以下简称"通商" 或"本所")接受华熙生物科技股份有限公司(以下简称"公司")委托，指派本所 律师出席了公司于 2025 年 6 月 11 日召开的 2024 年年度股东大会(以下简称"本 次股东大会")，并就本次股东大会的相关事项出具本法律意见书。 本法律意见书仅供公司本次股东大会之目的使用，本所律师同意将本法律意 见书随公司本次股东大会其他信息披露资料一并 ...

| 证券代码：688363 证券简称：华熙生物 公告编号：2025-021 | | | | | | | --- | --- | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | 一、 会议召开和出席情况 | | | | | | | （一） 股东大会召开的时间：2025 年 06 日 | | 月 11 | | | | | （二） 股东大会召开的地点：浙江省杭州市钱塘区海达北路 号康洲科创园 | | | | 399 | | | B1 座 1 层 | | | | | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | | | | 其持有表决权数量的情况： | | | | | | | 普通股股东人数 | | | | 188 | ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Huaxi Biological Technology Co., Ltd. The third board of directors has been elected for a term of three years, and key management positions have been filled. Group 1: Board of Directors Election - The third board of directors was elected during the annual general meeting on June 11, 2025, with Zhao Yan, Guo Jiajun, Li Yizheng, Wang Hui, Yu Jing, and Chen Yuxin as non-independent directors, and Yao Yang, Chen Daliang, and Xu Wenming as independent directors [1][2] - Zhao Yan was elected as the chairman of the third board of directors, with a term starting from the approval date until the end of the board's term [2] - The board established several specialized committees, including the Strategy Committee, Audit Committee, Nomination Committee, Compensation and Assessment Committee, ESG Committee, and Risk Management Committee, with independent directors holding a majority in key committees [2][3] Group 2: Senior Management Appointments - Zhao Yan was appointed as the General Manager, with Guo Jiajun, Li Yizheng, Wang Hui, and Xiang Maogong appointed as Deputy General Managers. Li Yizheng also serves as the Board Secretary, and Wang Hui as the Chief Financial Officer [4] - The appointments of senior management personnel were approved by the Nomination Committee, and their qualifications were reviewed accordingly [4] - Li Yizheng holds the qualification certificate for the Board Secretary of the Shanghai Stock Exchange's Sci-Tech Innovation Board, confirming his eligibility for the position [4] Group 3: Management Profiles - Zhao Yan, born in July 1966, holds a bachelor's degree in biology and an MBA from Fordham University. She has held various leadership roles within the company since 2000 [5] - Guo Jiajun, born in September 1975, has an MBA from Fordham University and has served in various managerial positions within the company since 2002 [6] - Li Yizheng, born in September 1984, holds a master's degree in investment studies and has extensive experience in investment banking prior to joining the company in 2021 [7] - Wang Hui, born in September 1983, is a CPA and has held various financial management roles before joining the company in September 2023 [8] - Xiang Maogong, born in February 1984, has a background in microbiology and has worked in various roles in the pharmaceutical industry [8]

证券代码：688363 证券简称：华熙生物 公告编号：2025-022 华熙生物科技股份有限公司 关于公司董事会完成换届选举 暨聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 11 日召开 公司 2024 年年度股东大会，选举产生了公司第三届董事会成员。同日，公司召 开了第三届董事会第一次会议，选举产生了第三届董事会董事长、第三届董事会 各专门委员会委员及召集人，并聘任高级管理人员。具体情况公告如下： 一、 董事会换届选举情况 （一）第三届董事会成员 经公司 2024 年年度股东大会选举，赵燕女士、郭珈均先生、李亦争先生、 汪卉先生、于静女士、陈玉鑫先生当选为公司第三届董事会非独立董事，姚洋先 生、陈达亮先生、徐文鸣先生当选为公司第三届董事会独立董事。第三届董事会 任期为自公司股东大会审议通过之日起三年。上述董事个人简历详见公司于 2025 年 5 月 20 日在上海证券交易所披露的《华熙生物科技股份有限公司关于董 事会换届选举的公告 ...